07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Teva, Impax, J&J neurology news

Johnson & Johnson's Alza Corp. subsidiary and Ortho-McNeil-Janssen Pharmaceuticals Inc. unit filed suit in the U.S. District Court for the District of Delaware alleging that an ANDA from Teva and Impax for a generic version...
07:00 , May 17, 2010 |  BC Week In Review  |  Company News

J&J, Watson neurology news

The U.S. Court of Appeals for the Federal Circuit denied an appeal by Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. division to overturn a 2009 ruling by the U.S. District Court for the District of Delaware...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Biovail, Watson cardiovascular, drug delivery, generics news

BVF and WPI's Andrx Pharmaceuticals Inc. settled all outstanding litigation related to a generic version of BVF's hypertension and angina drug Cardizem LA . Andrx received a license to IP for a generic version of...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Company News

Eurand board of directors update

Eurand N.V. (EURX), Amsterdam, the Netherlands   Business: Drug delivery   Appointed: Angelo Malahias, former president and CFO of Watson Pharmaceuticals Inc. 's Andrx Corp. subsidiary, as a non-executive director; and Rolf Classon, formerly interim...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

Insmed management update

Insmed Inc. (INSM), Richmond, Va.   Business: Musculoskeletal, Endocrine   Hired: Steve Glover as president of INSM's follow-on biologics business, formerly SVP and general manager of Andrx Corp. 's Andrx Laboratories LLC and Andrx Therapeutics...
07:00 , Mar 12, 2007 |  BC Week In Review  |  Company News

Biovail, Anchen Pharmaceuticals Inc., GlaxoSmithKline, Impax, Teva Pharmaceuticals Industries Ltd., Watson neurology news

The parties settled litigation related to generic versions of BVF's depression drug Wellbutrin XL bupropion. BVF dismissed its suits against IPXL and WPI. The settlement allows TEVA, which launched a 300 mg dose of the...
08:00 , Nov 20, 2006 |  BC Week In Review  |  Company News

Shire Pharmaceuticals Group plc, Watson neurology news

SHP subsidiary Shire Laboratories Inc. filed lawsuits against WPI subsidiary Andrx Corp. in the U.S. District Courts for the District of New Jersey and for the Southern District of Florida. The suit alleges that Andrx's...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Company News

Andrx, Watson deal

WPI completed its previously announced acquisition of generics and drug delivery company ADRX for $1.9 billion in cash (see BioCentury, March 20). Andrx Corp. (ADRX), Fort Lauderdale, Fla.   Watson Pharmaceuticals Inc. (WPI), Corona, Calif....
07:00 , Apr 10, 2006 |  BC Week In Review  |  Clinical News

ACTOplus met XR regulatory update

Takeda submitted an NDA for once-daily ACTOplus met XR, an extended-release version of ACTOplus met, to treat Type II diabetes. The application was submitted on March 31. ACTOplus met, which was approved by FDA last...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Company News

Vernalis management update

Vernalis plc (LSE:VER; VNLS), Winnersh, U.K.   Business: Cancer, Cardiovascular, Neurology   Hired: Rick Henson as VP of U.S. sales, formerly SVP of sales at Andrx Corp.'s Andrx Labs LLC unit; and Joseph Canny as...